ArticleMedicine2025
Possible recurrence of neuromuscular block following balloon dilation for bronchial stenosis in a young patient after bilateral lung transplantation: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSugammadex is a synthetic cyclodextrin derivative that reverses the effects of nondepolarizing neuromuscular blockers through selective encapsulation. Residual neuromuscular blockade (NMB) after extubation can lead to adverse events such as hypoxia and cardiac arrest. We encountered a case of residual NMB, despite the appropriate use of NMB monitoring and sugammadex, as recommended by the American Society of Anesthesiologists. PATIENT CONCERNS: A 27-year-old female underwent balloon dilatation under general anesthesia for left bronchial stenosis after lung transplantation. Rocuronium (50 mg) was administered for intubation, with 10 mg intermittently administered to maintain a train-of-four (TOF) count of <2. At the conclusion of the procedure, sugammadex (150 mg) was administered at a TOF count of 3. The patient was extubated with a TOF ratio of 100%. Fifteen minutes after transfer to the ward and 30 minutes after sugammadex administration, the patient developed respiratory distress and erythema on her trunk and upper limbs, exhibiting possible symptoms of anaphylaxis. The emergency team administered adrenaline via intramuscular injection. Despite this, the respiratory symptoms worsened. DIAGNOSES: Difficulty in breathing was possibly due to recurrent NMB caused by residual muscle relaxants that were not fully reversed.
interventionsThe patient was reintubated and transferred to the intensive care unit. Bronchoscopy performed after reintubation did not reveal signs of anaphylactic airway swelling. OUTCOMES: The patient's respiratory condition improved, and she was extubated the following morning. After extubation, she recalled being unable to breathe or move during the follow-up bronchoscopy. Plasma histamine and serum tryptase levels were measured 2 and 24 hours after the suspected anaphylactic episode, showing no increase in the levels. LESSONS: This case highlights that neuromuscular monitoring and adherence to sugammadex dosing guidelines do not entirely eliminate the risk of recurarization, which may present with anaphylaxis-like symptoms, complicating the diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.